A phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexa-caftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Sub-jects with Non-F508del CFTR Genotypes (VX21-445-125)

This study will evaluate the long-term safety, efficacy and pharmacodynamics of ELX/TEZ/IVA in participants with cystic fibrosis (CF) with at least 1 non-F508del ELX/TEZ/IVA-responsive CF transmembrane conductance regulator (CFTR) gene mutation.